Lupin gets USFDA approval for Paraxetin tablets
Lupin Limited has informed The Bombay Stock Exchange Ltd and National Stock Exchange Ltd. on January 23, 2017, that it has received final approval from the US Food and Drug Administration.
The company has received USFDA approval for Paraxetin Extended Release Tablets USP, 12.5 mg, 25 mg, which is a generic version of Apotex Technologies, Inc’s Paxil CR® tablets, 12.5 mg, 25 mg and 37.5 mg.
Lupin Ltd is a pharmaceuticals major based in Mumbai, having current market capitalisation of Rs 66,149.44 crore. The stock has is up today and has made intra-day high at Rs 1490, up by more than 1.50 per cent on Monday morning.